Abstract

Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy and in some cases lower toxicity than conventional treatment. Although targeted therapeutics have helped immensely in the treatment of several cancers, like chronic myelogenous leukemia, colon cancer, and breast cancer, the benefit of these agents in the treatment of lung cancer remains limited, in part due to the development of drug resistance. In this review, we discuss the mechanisms of drug resistance and the current strategies used to treat lung cancer. A better understanding of these drug-resistance mechanisms could potentially benefit from the development of a more robust personalized medicine approach for the treatment of lung cancer.

Details

Title
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies
Author
Sechler, Marybeth; Cizmic, Amber D; Avasarala, Sreedevi; Michelle Van Scoyk; Brzezinski, Christine; Kelley, Nicole; Bikkavilli, Rama Kamesh; Winn, Robert A
Pages
25-36
Section
Review
Publication year
2013
Publication date
2013
Publisher
Taylor & Francis Ltd.
ISSN
1178-7066
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2222840056
Copyright
© 2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.